We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MRP:JSEMr Price Group Limited Analysis

Data as of 2026-05-24 - not real-time

ZAC 15,311.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Mr Price Group is trading at roughly ZAc 15,300, which sits just below its 20‑day SMA (≈15,470) and well under its 50‑day SMA, confirming a short‑term bearish technical bias. However, the DCF‑derived fair value of about ZAc 39,400 suggests an upside of roughly 60%, while the stock boasts a low beta (≈0.10), a solid dividend yield of 5.99% and a payout ratio of 64%, indicating strong cash generation. The company’s fundamentals are robust – revenue is growing at 5.2% YoY, ROE stands near 29%, and free cash flow exceeds ZAc 6.5 bn – and volume has been picking up, supporting liquidity.
On the news side, investor sentiment has been dented by a contentious NKD acquisition in Europe, with a shareholder urging JSE intervention and the stock hitting a 52‑week low amid lingering doubts. Conversely, the Studio 88 athleisure chain has delivered a notable earnings boost, highlighting the group’s growth engines. Balancing the deep valuation gap and dividend appeal against acquisition risk leads to a hold stance in the near term, but a clear buying case for medium‑ and long‑term horizons.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 4/10

Key Factors

  • NKD acquisition uncertainty and recent 52‑week low
  • Bearish technical positioning below short‑term SMAs
  • Strong support around ZAc 14,753

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Significant valuation upside versus DCF fair value
  • Sustained high dividend yield and solid cash flow
  • Growth contribution from Studio 88 and potential synergies from NKD

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Robust ROE and consistent profitability
  • Dividend sustainability with a 64% payout ratio
  • Long‑run undervaluation and low market beta

Key Metrics & Analysis

Financial Health

Revenue Growth5.20%
Profit Margin9.00%
P/E Ratio10.9
ROE28.55%
ROA11.10%
Debt/Equity61.77
P/B Ratio3.0
Op. Cash FlowZAC8.5B
Free Cash FlowZAC6.6B

Technical Analysis

TrendBearish
RSI45.2
SupportZAC 14,753.00
ResistanceZAC 16,433.00
MA 20ZAC 15,473.35
MA 50ZAC 15,787.02
MA 200ZAC 18,613.66
MACDBullish
VolumeIncreasing
Fear & Greed Index91.61

Valuation

Fair ValueZAC 39,371.13
Target PriceZAC 24,348.66
Upside/Downside59.03%
GradeUndervalued
TypeBlend
Dividend Yield5.99%

Risk Assessment

Beta0.10
Volatility27.27%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.